United Therapeutics Corp (FRA:UTH)
€ 459 +13.1 (+2.94%) Market Cap: 20.06 Bil Enterprise Value: 17.35 Bil PE Ratio: 19.28 PB Ratio: 3.86 GF Score: 85/100

United Therapeutics Corp at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 01:40PM GMT
Release Date Price: €93.5 (+2.19%)
Chris Shibutani
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

My name is Chris Shibutani, and welcome to this presentation of United Therapeutics at the Cowen Healthcare Conference. I'm a member of the biotech research team and really appreciate you joining us today.

We have a special treat with a fireside chat discussion with the United Therapeutics management. We recently upgraded the stock, which has been around for a long time. And I think it's high time for people to pay attention. We look at the story, many under [tensions,] presumptions that people have had about some of the trends within the business have changed. And it's worth taking a look -- a closer look in the debate. I'm joined on stage here by Michael Benkowitz, who is, get your title correct, President and Chief Operating Officer.

Michael I. Benkowitz
United Therapeutics Corporation - President & COO

Got it.

Chris Shibutani
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot